Stock comparison
Ligand Pharmaceuticals
LGND$6.06BHealthcare Market cap, Sector
SANOFI CONS HEALTHC IND L
SANOFICONR.NS$104.97BHealthcare Market cap, Sector
Overall winner
SANOFI CONS HEALTHC IND L
LGND 07 SANOFICONR.NS
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
LGND0wins
7winsSANOFICONR.NS
54D
B78
67C
A89
64C
B83
54D
B77
51D
A91
56D
A86
45D
A85
Side-by-side metrics
| Metric | LGND | SANOFICONR.NS |
|---|---|---|
| Market cap | $6.06B | $104.97B Winner |
| P/E (TTM) | Winner: 30.4x | 44.2x |
| EV/EBIT | 106.9x | 31.8x Winner |
| ROIC (TTM) | 5.61% | 59.15% Winner |
| Gross margin | Winner: 98.61% | 68.13% |
| Net margin | Winner: 55.95% | 27.35% |
| Revenue CAGR 5y | 2.64% | 27.01% Winner |
| EPS CAGR 5y | 16.8% | 20.67% Winner |
| Debt / Equity | 0.5x | 0.1x Winner |
| Dividend yield | 0.0% | - |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LGND leads on
- Net margin55.95%vs 27.35%+51%
- P/E (TTM)30.4xvs 44.2x+31%
- Gross margin98.61%vs 68.13%+31%
SANOFICONR.NS leads on
- Market cap$104.97Bvs $6.06B+94%
- ROIC (TTM)59.15%vs 5.61%+91%
- Revenue CAGR 5y27.01%vs 2.64%+90%
- Debt / Equity0.1xvs 0.5x+86%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.